Mesoblast Limited - American Depositary Shares (MESO)
15.62
+3.28 (26.58%)
NASDAQ · Last Trade: Jul 19th, 3:13 AM EDT
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · July 18, 2025
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.
Via Benzinga · July 18, 2025

Via Benzinga · January 10, 2025
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · July 18, 2025
Via Benzinga · July 18, 2025
Via Benzinga · July 18, 2025
Via Benzinga · July 18, 2025
Via Benzinga · July 16, 2025
Via Benzinga · July 2, 2025
Shares of The Greenbrier Companies, Inc. (NYSE: GBX) rose sharply in today's pre-market trading after the company posted stronger-than-expected results for the third quarter. The company posted quarterly earnings of $1.86 per share, beating market estimates of 98 cents per share.
Via Benzinga · July 2, 2025
Via Benzinga · July 1, 2025
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · July 1, 2025
Mesoblast plans to file a BLA for Revascor by year-end after aligning with FDA on trial design, potency assays, and manufacturing controls.
Via Benzinga · July 1, 2025
Via Benzinga · July 1, 2025
Via Benzinga · June 20, 2025
Via Benzinga · June 20, 2025
The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease.
Via Stocktwits · June 12, 2025

Via Benzinga · June 4, 2025
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · April 11, 2025
Via Benzinga · April 11, 2025
Via Benzinga · April 11, 2025
Don't be scared off up by the recent Trump FDA overhaul. The changes are very positive for Capricor Therapeutics moving forward (2025–2028).
Via Talk Markets · April 1, 2025